ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1505647 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-15

Study Completion Date

2020-10-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

NCT00546819

Herpes Zoster

COMPLETED PHASE2

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

NCT00550745

Herpes Zoster

COMPLETED PHASE4

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

NCT00534248

Shingles

COMPLETED PHASE3

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

NCT00322231

Herpes Zoster

COMPLETED PHASE3

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

NCT01556451

Herpes Zoster Shingles

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Herpes Zoster Shingles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated Cohort

Participants vaccinated with at least one dose of ZOSTAVAX™

ZOSTAVAX™

Intervention Type BIOLOGICAL

ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use

Unvaccinated Comparison Cohort

Participants who are not yet vaccinated with any zoster vaccine

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZOSTAVAX™

ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zoster Vaccine Live

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes